Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Olaparib Monotherapy in HRRm/HRD-Positive Advanced Solid Tumors
2018-003007-19Phase 2Active
- Sponsor
- Merck & Co.
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of olaparib in cancer, homologous recombination deficiency (HRD) and prostate cancer (PCa), sponsored by Merck & Co. Primary endpoint: Objective response rate (ORR). Started Oct 2018; status: active.
02
Drugs
olaparib
03
Conditions
cancerhomologous recombination deficiency (HRD)prostate cancer (PCa)
Beyond the preview
Go deeper on 2018-003007-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003007-19.